Cholesterol Lowering Drugs And The Risk Of Hemorrhagic Stroke

Main Category: Cholesterol
Also Included In: Stroke;  Neurology / Neuroscience;  Clinical Trials / Drug Trials
Article Date: 13 Dec 2007 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:4 stars

3.83 (6 votes)

Healthcare Prof:4 and a half stars

4.5 (2 votes)

Article Opinions: 1 posts

People taking cholesterol lowering drugs such as atorvastatin after a stroke may be at an increased risk of hemorrhagic stroke, or bleeding in the brain, a risk not found in patients taking statins who have never had a stroke. But researchers caution the risk must be balanced against the much larger overall benefit of the statin in reducing the total risk of a second stroke and other cardiovascular events when making treatment decisions. The research is published in the December 12, 2007, online issue of Neurology®, the medical journal of the American Academy of Neurology.

For the study, researchers conducted a secondary analysis of the results of the Stroke Prevention with Aggressive Reduction in Cholesterol Levels (SPARCL) clinical trial. The trial enrolled 4,731 people who were within one to six months of having had a stroke or transient ischemic attack, or mini-stroke, and with no history of heart disease. Half of the participants received atorvastatin and half received a placebo. The participants were then followed for an average of four and a half years.

Overall, treatment was associated with a 16-percent reduction in total stroke, the study's primary endpoint, as well as significant reductions in coronary heart events. However, secondary analysis found that the overall reduction in stroke included an increase in the risk of brain hemorrhage. Of those people randomized to atorvastatin, the study found 2.3 percent experienced a hemorrhagic stroke during the study compared to 1.4 percent of those taking placebo. The study also found there was a 21-percent reduction in ischemic stroke, a more common type of stroke involving a block in the blood supply to the brain, among people taking atorvastatin.

Other factors were also found to increase the risk of brain hemorrhage. For example, those who had experienced a hemorrhagic stroke prior to the study were more than five times as likely to suffer a second stroke of this kind. Men were also nearly twice as likely as women to suffer a hemorrhagic stroke. People with severe high blood pressure at their last doctor's visit prior to the hemorrhagic stroke had over six times the risk of those with normal blood pressure.

"Although treatment of patients with a stroke or transient ischemic attack was clearly associated with an overall reduction in a second stroke, hemorrhagic stroke was more frequent in people treated with atorvastatin, in those with a prior hemorrhagic stroke, in men and in those with uncontrolled hypertension," according to study author Larry B. Goldstein, MD, with Duke University Medical Center in Durham, North Carolina, and Fellow of the American Academy of Neurology. "This risk of hemorrhagic stroke also increased with age."

"Treatment with atorvastatin did not disproportionately increase the frequency of brain hemorrhage associated with these other factors. The risk of hemorrhage in patients who have had a transient ischemic attack or stroke must be balanced against the benefits of cholesterol-lowering drugs in reducing the overall risk of a second stroke, as well as other cardiovascular events," said Goldstein.

The SPARCL trial was funded by Pfizer, the maker of atorvastatin.

The American Academy of Neurology, an association of more than 20,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer's disease, epilepsy, Parkinson disease, and multiple sclerosis.

For more information about the American Academy of Neurology, visit http://www.aan.com

American Academy of Neurology (AAN)
1080 Montreal Ave.
St. Paul, MN 55116
United States
http://www.neurology.org

Article adapted by Medical News Today from original press release.
Visit our cholesterol section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
American Academy of Neurology. "Cholesterol Lowering Drugs And The Risk Of Hemorrhagic Stroke." Medical News Today. MediLexicon, Intl., 13 Dec. 2007. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/91617.php>

APA
American Academy of Neurology. (2007, December 13). "Cholesterol Lowering Drugs And The Risk Of Hemorrhagic Stroke." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/91617.php.

Please note: If no author information is provided, the source is cited instead.




Cholesterol

What Is Cholesterol?

Cholesterol is a fat (lipid) which is produced by the liver and is crucial for normal body functioning. Cholesterol exists in the outer layer of every cell in our body and has many functions. Read more...

Most Popular Articles



Follow Our Cholesterol News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Cholesterol Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »